Sailun Bio released its 2026 interim report on August 22, 2026. Total operating revenue was 104 million yuan, net profit attributable to the parent company was 35.6513 million yuan, and net cash inflow from operating activities was 8.0366 million yuan. The company's latest asset-liability ratio was 5.40 percent, up 1.83 percentage points from the previous quarter and up 2.87 percentage points from the same period last year. The latest gross margin was 78.28 percent, the latest return on equity was 3.18 percent, and diluted earnings per share was 0.33 yuan. The company's latest inventory turnover ratio was 0.54 times, and total asset turnover fell 0.45 percent from the same period last year. The company had 5,364 shareholders, and the top ten shareholders held 74.1553 million shares, accounting for 68.52 percent of total share capital.
Shanghai Serum Bio-Technology Co. Ltd. AInterim report shows net profit of 35.65 million yuan, indicating profitability.